Calcilytix Therapeutics, Inc., a BridgeBio company
4 clinical trials · Sponsor
◉ Watch Calcilytix Therapeutics, Inc., a BridgeBio company
| Record | Firm | Date |
|---|---|---|
| Pharmacokinetics, Efficacy, and Safety of Encaleret in Pediatric Participants With Autosomal Dominant Hypocalcemia Type 1 (ADH1) (NCT07080385) | Calcilytix Therapeutics, Inc., a BridgeBio company | 2026-01-30 |
| Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1 (NCT05680818) | Calcilytix Therapeutics, Inc., a BridgeBio company | 2023-01-06 |
| ADH1 and ADH2 Disease Monitoring Study (DMS) (NCT05227287) | Calcilytix Therapeutics, Inc., a BridgeBio company | 2022-01-20 |
| Safety, Tolerability, and Efficacy of Encaleret in Participants With Autosomal Dominant Hypocalcemia (ADH) Type 1 (NCT04581629) | Calcilytix Therapeutics, Inc., a BridgeBio company | 2020-09-20 |
Track Calcilytix Therapeutics, Inc., a BridgeBio company automatically
Every clearance here is in the API, with alerts when new ones post.